# Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection

> **NCT02027116** · PHASE1 · COMPLETED · sponsor: **GeneOne Life Science, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** VGX-6150

## Key facts

- **NCT ID:** NCT02027116
- **Lead sponsor:** GeneOne Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-07
- **Final completion:** 2017-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02027116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02027116, "Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02027116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*